Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Hye Ryun Kim; Mark M. Awad; Alejandro Navarro; Maya Gottfried; Solange Peters; Tibor Csőszi; Parneet Cheema; Delvys Rodríguez‐Abreu; Mirjana Wollner; James Chih‐Hsin Yang; Julien Mazières; Francisco J. Orlandi; Alexander Luft; Mahmut Gümüş; Terufumi Kato; Gregory P. Kalemkerian; Yiwen Luo; Melissa L. Santorelli; M. Catherine Pietanza; Charles M. Rudin

doi:10.1016/j.jtocrr.2023.100572

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

First-line pembrolizumab plus EP therapy maintained HRQoL in patients with ES-SCLC and may be associated with greater improvement than placebo plus EP. Together with the efficacy and safety findings in KEYNOTE-604, HRQoL data support the benefit of pembrolizumab in ES-SCLC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2023) studied this question.

synapsesocial.com/papers/69d9398834ded318bb684174 https://doi.org/10.1016/j.jtocrr.2023.100572

View Full Paper

Ask AI

Bookmark

Share

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading